Christoph Zeyen, Maria Kinberger, Helene Kriedemann, Frieder Pfäfflin, Pinkus Tober-Lau, Leu Huang, Victor Max Corman, Alexander Nast, Leif Erik Sander, Florian Kurth, Ricardo Niklas Werner
BACKGROUND: Cases of mpox have been reported worldwide since May 2022. Limited knowledge exists regarding the long-term course of this disease. To assess sequelae in terms of scarring and quality of life (QoL) in mpox patients 4-6 months after initial infection. METHODS: Prospective observational study on clinical characteristics and symptoms of patients with polymerase chain reaction (PCR)-confirmed mpox, including both outpatients and inpatients. Follow-up visits were conducted at 4-6 months, assessing the Patient and Observer Scar Assessment Scale (POSAS), the Dermatology Life Quality Index (DLQI) and sexual impairment, using a numeric rating scale (NRS) from 0 to 10...
March 15, 2024: BMC Infectious Diseases